UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2020

		Individual quarter		Cumulativ	e quarter
	Note	Current year quarter 30/09/2020 RM'000	Preceding year quarter 30/09/2019 RM'000	Current year- to-date 30/09/2020 RM'000	Preceding year-to-date 30/09/2019 RM'000
Revenue		40,101	29,408	104,678	88,169
Cost of sales		(29,518)	(20,234)	(74,842)	(61,860)
Gross profit		10,583	9,174	29,836	26,309
Other operating income		100	50	472	372
Distribution costs		(2,730)	(2,634)	(7,325)	(7,153)
Administration expenses		(4,717)	(3,722)	(14,853)	(10,766)
Finance costs		(297)	(231)	(1,085)	(673)
Profit before tax		2,939	2,637	7,045	8,089
Tax expense	B5	(661)	(619)	(1,950)	(1,693)
Profit for the financial period		2,278	2,018	5,095	6,396
Other comprehensive income, net of tax		-	-	-	
Total comprehensive income		2,278	2,018	5,095	6,396
Profit attributable to: Owners of the parent Non-controlling interests		1,834 444	2,018	4,651	6,396
		2,278	2,018	5,095	6,396
Total comprehensive income attributable to:					
Owners of the parent		1,834	2,018	4,651	6,396
Non-controlling interests		444	-	444	
		2,278	2,018	5,095	6,396
Earnings per ordinary share attributable to owners of the parent:					
- Basic (sen)	B14	0.91	1.11	2.41	3.51
- Diluted (sen)	B14	0.91	1.11	2.41	3.51

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2019 and the accompanying explanatory notes attached to these interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2020

	Note	As at 30/09/2020 RM'000	Audited As at 31/12/2019 RM'000
Non-current asset			
Property, plant and equipment		66,140	57,660
Right-of-use assets		11,707	12,050
Investment property		5,621	5,653
Biological assets		1,755	-
Goodwill		4,356	-
Other investment	B8 _	32	40
	<u>-</u>	89,611	75,403
Current assets			
Inventories		30,169	33,819
Trade and other receivables		36,094	30,411
Current tax assets		358	43
Cash and bank balances and short term funds	_	24,438	9,209
	_	91,059	73,482
Total assets	_	180,670	148,885
Equity			
Share capital	D16	103,618	92,114
Reorganisation debit balance	B16	(59,489)	(59,489)
Retained earnings	_	77,351	74,709
Total attributable to owners of the parent		121,480	107,334
Non-controlling interests	_	3,795	-
Total equity	_	125,275	107,334
Non-current liabilities			
Borrowings	В9	32,382	25,221
Deferred tax liabilities		342	342
	-	32,724	25,563
Current Liabilities	_	<u> </u>	· · · · · · · · · · · · · · · · · · ·
Trade and other payables		18,693	12,953
Borrowings	В9	2,323	2,066
Lease liabilities		, -	191
Current tax liabilities		1,655	778
	-	22,671	15,988
Total liabilities	_	55,395	41,551
Total equity and liabilities	_	180,670	148,885
Net assets per share attributable to owners of the parent (RM)	B15	0.60	0.59

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2019 and the accompanying explanatory notes attached to these interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2020

	<> Attributable to ov		ners of the parent> Distributable			
	Share capital RM'000	Reorganisation debit balance RM'000	Retained earnings RM'000	Total attributable to owners of the parent RM'000	Non- controlling interest RM'000	Total equity RM'000
Balance as at 1 January 2020	92,114	(59,489)	74,709	107,334	-	107,334
Profit for the financial period Other comprehensive income, net of tax Total comprehensive income	- -	- - -	4,651 - 4,651	4,651 - 4,651	444 - 444	5,095 - 5,095
Transactions with owners: Issuance of new ordinary shares Dividends paid Non-controlling interests arising from acquisition of subsidiaries	11,504	- - -	(2,009)	11,504 (2,009)	3,351	11,504 (2,009) 3,351
Total transactions with owners	11,504	-	(2,009)	9,495	3,351	12,846
Balance as at 30 September 2020	103,618	(59,489)	77,351	121,480	3,795	125,275
Balance as at 1 January 2019 Effects of adoption of MFRS 16 Balance as at 1 January 2019, as restated	92,114 - 92,114	(59,489) - (59,489)	71,569 (18) 71,551	104,194 (18) 104,176	- - -	104,194 (18) 104,176
Profit for the financial period Other comprehensive income, net of tax Total comprehensive income	- - -	- -	6,396 - 6,396	6,396 - 6,396	- - -	6,396 - 6,396
Transactions with owners: Dividends paid Total transactions with owners		<u>-</u>	(5,478) (5,478)	(5,478) (5,478)	<u>-</u>	(5,478) (5,478)
Balance as at 30 September 2019	92,114	(59,489)	72,469	105,094	-	105,094

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2019 and the accompanying explanatory notes attached to these interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2020

Cash flows from operating activities Profit before tax 7,045 8,089 Adjustments for:		Current year- to-date 30/09/2020 RM'000	Preceding year-to-date 30/09/2019 RM'000
Adjustments for: Depreciation 1,176 887 Inventories written off 1,582 309 Inventories written down 552 540 Impairment loss on receivables 240 155 Impairment loss on other investment 8 12 Interest expense 1,085 673 Fair value gain on biological assets (5) - Fair value gain on biological assets (5) - Fair value gain on biological assets (5) - Interest income (144) (183) Urrealised loss on foreign currency exchange 255 61 Operating profit before working capital changes 11,794 10,543 Changes in working capital: 11,794 10,543 Trade and other receivables (1,896) 6,491 Trade and other payables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operating activities (1,395) (2,342) Net cash from investing activities 2,566 5,244	Cash flows from operating activities		
Depreciation	Profit before tax	7,045	8,089
Inventories written off	Adjustments for:		
Inventories written down 552 540 Impairment loss on receivables 240 155 Impairment loss on oreceivables 240 155 Impairment loss on oreceivables 8 12 Interest expense 1,085 673 Fair value gain on biological assets (5) - Interest income (144) (183) Unrealised loss on foreign currency exchange 255 61 Operating profit before working capital: 11,794 10,543 Changes in working capital: 1 11,794 10,543 Changes in working capital: 1 1,996 6,491 Trade and other receivables (1,896) 6,491 6,491 Trade and other payables (1,520) (3,112) (23,220) Cash generated from operations 11,445 7,666 7,066 Tax paid (1,395) (2,342) (2,342) Net cash from operating activities 5,969 (15,288) Purchase of other investing activities 10,050 5,324 Purchase	Depreciation	1,176	887
Impairment loss on receivables 240 155 Impairment loss on other investment 8 12 Interest expense 1,085 673 Fair value gain on biological assets (5) - Interest income (144) (183) Unrealised loss on foreign currency exchange 255 61 Operating profit before working capital changes 11,794 10,543 Changes in working capital: 11,794 10,543 Changes in working capital: 11,794 10,543 Changes in working capital: 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 5,969 (15,288) Purchase of property, plant and equipment (5,969) (15,288) Purchase of property, plant and equipment (5,969) (15,288) <tr< td=""><td>Inventories written off</td><td>1,582</td><td>309</td></tr<>	Inventories written off	1,582	309
Impairment loss on other investment 8 12 Interest expense 1,085 673 673 Fair value gain on biological assets 1,085 673 673 1444 183 1444 183 1444 1444 1444 1445 1455 1445 1455	Inventories written down	552	540
Interest expense 1,085 673 Fair value gain on biological assets (5) - Interest income (144) (183) Unrealised loss on foreign currency exchange 255 61 Operating profit before working capital changes 11,794 10,543 Changes in working capital: 11,794 10,543 Inventories 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities 7,138 (168) Interest paid (1,085	Impairment loss on receivables	240	155
Fair value gain on biological assets (5) - Interest income (144) (183) Unrealised loss on foreign currency exchange 255 61 Operating profit before working capital changes 11,794 10,543 Changes in working capital: 11,794 10,543 Changes in working capital: 11,896 6,256 Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities Value 10,050 5,324 Cash flows from investing activities Value 10,050 5,324 Cash flows from investing activities Value 11,209 - Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net drawdown/(repay	Impairment loss on other investment	8	12
Interest income (144) (183) Unrealised loss on foreign currency exchange 255 61 Operating profit before working capital changes 11,794 10,543 Changes in working capital: 11,794 10,543 Inventories 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Verash flows from investing activities 5,969 (15,288) Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of	Interest expense	1,085	673
Unrealised loss on foreign currency exchange 255 61 Operating profit before working capital changes 11,794 10,543 Changes in working capital: 3,067 (6,256) Inventories 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities 5,969 (15,288) Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities 7,138 (168) Cash flows from financing activities 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478)	Fair value gain on biological assets	(5)	-
Operating profit before working capital changes 11,794 10,543 Changes in working capital: 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities 5,969 (15,288) Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - <	Interest income	(144)	(183)
Changes in working capital: 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,2	Unrealised loss on foreign currency exchange	255	61
Inventories 3,067 (6,256) Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213		11,794	10,543
Trade and other receivables (1,896) 6,491 Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and			
Trade and other payables (1,520) (3,112) Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities \$\text{Variable of property, plant and equipment}}\$ \$\text{(5,969)}\$ \$\text{(15,288)}\$ Purchase of other investment \$- \$\text{(50)}\$ Acquisition of subsidiaries, net of cash acquired \$\text{(1,209)}\$ \$\text{-1}\$ Interest received \$\text{144}\$ \$\text{183}\$ Net cash used in investing activities \$\text{(7,034)}\$ \$\text{(15,155)}\$ Cash flows from financing activities \$\text{(1,085)}\$ \$\text{(673)}\$ Net drawdown/(repayment) of borrowings \$\text{7,138}\$ \$\text{(168)}\$ Interest paid \$\text{(1,085)}\$ \$\text{(673)}\$ Dividend paid \$\text{(2,009)}\$ \$\text{(5,478)}\$ Payment of lease liabilities \$\text{(9)}\$ \$\text{-}\$ Net proceeds from issuance of shares \$\text{8,178}\$ \$\text{-}\$ Net cash from/(used in) financing activities \$\text{15,229}\$			
Cash generated from operations 11,445 7,666 Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities \$\text{2.248}\$ Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435			
Tax paid (1,395) (2,342) Net cash from operating activities 10,050 5,324 Cash flows from investing activities \$\text{Purchase of property, plant and equipment}}\$ (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities \$\text{Net drawdown/(repayment) of borrowings}\$ 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435			(3,112)
Net cash from operating activities 10,050 5,324 Cash flows from investing activities Verchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities Vertical Company of the co	•		
Cash flows from investing activities Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities 8 (168) Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435	Tax paid	(1,395)	(2,342)
Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities 7,138 (168) Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435	Net cash from operating activities	10,050	5,324
Purchase of property, plant and equipment (5,969) (15,288) Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities 7,138 (168) Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435	Cash flows from investing activities		
Purchase of other investment - (50) Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities 8 (168) Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435	_	(5.969)	(15.288)
Acquisition of subsidiaries, net of cash acquired (1,209) - Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities Value of the cash investing activities Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435		-	
Interest received 144 183 Net cash used in investing activities (7,034) (15,155) Cash flows from financing activities Net drawdown/(repayment) of borrowings 7,138 (168) Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435		(1,209)	-
Cash flows from financing activities Net drawdown/(repayment) of borrowings Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) Net proceeds from issuance of shares Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents at beginning of financial period 9,209 24,435			183
Net drawdown/(repayment) of borrowings7,138(168)Interest paid(1,085)(673)Dividend paid(2,009)(5,478)Payment of lease liabilities(9)-Net proceeds from issuance of shares8,178-Net cash from/(used in) financing activities12,213(6,319)Net increase/(decrease) in cash and cash equivalents15,229(16,150)Cash and cash equivalents at beginning of financial period9,20924,435	Net cash used in investing activities	(7,034)	(15,155)
Net drawdown/(repayment) of borrowings7,138(168)Interest paid(1,085)(673)Dividend paid(2,009)(5,478)Payment of lease liabilities(9)-Net proceeds from issuance of shares8,178-Net cash from/(used in) financing activities12,213(6,319)Net increase/(decrease) in cash and cash equivalents15,229(16,150)Cash and cash equivalents at beginning of financial period9,20924,435	Cash flows from financing activities		
Interest paid (1,085) (673) Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435		7 138	(168)
Dividend paid (2,009) (5,478) Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435			, ,
Payment of lease liabilities (9) - Net proceeds from issuance of shares 8,178 - Net cash from/(used in) financing activities 12,213 (6,319) Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435			
Net proceeds from issuance of shares8,178-Net cash from/(used in) financing activities12,213(6,319)Net increase/(decrease) in cash and cash equivalents15,229(16,150)Cash and cash equivalents at beginning of financial period9,20924,435		* * * *	(3,470)
Net cash from/(used in) financing activities12,213(6,319)Net increase/(decrease) in cash and cash equivalents15,229(16,150)Cash and cash equivalents at beginning of financial period9,20924,435	-		_
Net increase/(decrease) in cash and cash equivalents 15,229 (16,150) Cash and cash equivalents at beginning of financial period 9,209 24,435	-		(6.310)
Cash and cash equivalents at beginning of financial period 9,209 24,435	Net cash from/(used iii) illiancing activities	12,213	(0,319)
Cash and cash equivalents at beginning of financial period 9,209 24,435	Net increase/(decrease) in cash and cash equivalents	15,229	(16,150)
	•		

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2019 and the accompanying explanatory notes attached to these interim financial statements.

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

A1. Basis of preparation

The unaudited interim financial statements have been prepared in accordance with the requirements of MFRS 134 *Interim Financial Reporting* and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2019 and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2019.

A2. Significant accounting policies

The significant accounting policies and methods of computation adopted for the interim financial statements are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2019, except for the adoption of the following amendments to MFRSs during the financial period:

- Amendments to References to the Conceptual Framework in MFRS Standards
- Amendments to MFRS 3 Definition of a Business
- Amendments to MFRS 101 and MFRS 108 Definition of Material
- Amendments to MFRS 9, MFRS 139 and MFRS 7 Interest Rate Benchmark Reform

The adoption of the above amendments had no significant impact to the financial statements of the Group.

A3. Auditors' report

There was no qualification to the audited financial statements of the Company and its subsidiaries for the financial year ended 31 December 2019.

A4. Seasonal or cyclical factors

The business operations of the Group were not materially affected by any seasonal and cyclical factors during the current quarter and financial year-to-date under review.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

Save for the completion of the acquisition of 49% equity interests in One Lazuli Sdn Bhd ("OLSB"), Nor Lazuli Nutrition Sdn Bhd ("NLN") and Nor Livestock Farm Sdn Bhd ("NLF") on 1 July 2020 as per the Company's announcement on even date, there were no other unusual items affecting assets, liabilities, equity, net income or cash flows of the Group for the current quarter and financial year-to-date under review.

A6. Changes in estimates

There were no changes in estimates that have a material effect in the current quarter and financial year-to-date under review.

A7. Debt and equity securities

- (i) On 2 April 2020, the issued shares of the Company increased from 182,600,000 ordinary shares to 195,580,589 ordinary shares pursuant to a private placement of 12,980,589 new ordinary shares in the Company.
- (ii) On 23 June 2020, the issued shares of the Company further increased from 195,580,589 ordinary shares to 200,860,000 ordinary shares pursuant to the issuance of 5,279,411 new ordinary shares in the Company as partial purchase consideration for the acquisition of 49% equity interest in OLSB.

Save for the above, there were no other issuance, cancellation, repurchase, resale or repayment of debt and equity securities for the current quarter and financial year-to-date under review.

A8. Dividend

A final single tier dividend of 1.0 sen per ordinary share in respect of the financial year ended 31 December 2019 was approved by shareholders at the Company's Annual General Meeting on 16 June 2020. The dividend was paid on 15 July 2020 and had been accounted for in equity as an appropriation of retained earnings in the financial year ending 31 December 2020.

A9. Segmental information

The Group's operating segments are animal health products, food ingredients and others. These operating segments are required to be organised and managed separately according to the nature of products and services as well as specific expertise which require different business and marketing strategies. The segmental results are as follows:

	Individua	ıl quarter	Cumulative quarter		
	Current year quarter 30/09/2020 RM'000	Preceding year quarter 30/09/2019 RM'000	Current year- to-date 30/09/2020 RM'000	Preceding year-to-date 30/09/2019 RM'000	
Revenue					
Animal health products and equipment	32,192	21,960	80,162	66,371	
Food ingredients	7,120	6,805	22,544	19,931	
Others	789	643	1,972	1,867	
	40,101	29,408	104,678	88,169	
Profit before tax					
Animal health products and equipment	2,711	2,056	5,890	6,225	
Food ingredients	74	544	1,384	1,624	
Others	154	37	(229)	240	
	2,939	2,637	7,045	8,089	

A10. Property, plant and equipment

(i) Acquisitions and disposals

There were no material acquisitions and disposals during the current quarter and financial year-to-date under review.

(ii) Impairment losses

There were no material impairment losses during the current quarter and financial year-to-date under review.

(iii) Valuation

The Group has not carried out any valuation on its property, plant and equipment during the current quarter and financial year-to-date under review.

A11. Material events subsequent to the end of the quarter

There were no material events subsequent to the end of the current quarter that have not been reflected in this interim financial report.

A12. Changes in the composition of the Group

Save for the completion of the acquisition of 49% equity interests in OLSB, NLN and NLF on 1 July 2020 as per the Company's announcement on even date, there were no other changes in the composition of the Group during the current quarter and financial year-to-date under review.

A13. Contingent liabilities and contingent assets

There were no contingent liabilities or contingent assets as at the date of this report.

A14. Capital commitments

The capital commitments of the Group as at the end of the quarter under review were as follows:

	RM'000
Approved and contracted for:	
- Construction of GMP-compliant plant in Nilai, Negeri Sembilan	3,439
- Machineries and equipment	3,276
	6,715

A15. Significant related party transactions

The related party transactions during the current quarter and financial year-to-date under review are as follows:

	Individua Current year quarter 30/09/2020 RM'000	al quarter Preceding year quarter 30/09/2019 RM'000	Cumulati Current year-to-date 30/09/2020 RM'000	rive quarter Preceding year-to-date 30/09/2019 RM'000
NLF purchases feed from NLN	178	-	178	-
NLF purchases milk replacer from NLN	4	-	4	-
NLN purchases hay from NLF	13	-	13	-
OLSB purchases feed from NLN	5	-	5	-
OLSB provides transportation services to NLN	7	-	7	-
NLF purchases anti- inflammatory medication, mastitis medication, antibiotics, anti-parasitics and dairy milk machine parts from OLSB	23	-	23	-
NLF purchases milking machines from OLSB	167	-	167	-
NLN rents an office space from OLSB	3	-	3	-
NLF rents an office space from OLSB	1	-	1	-
NLF rents a farm land from Raja Mariam Binti Raja Rustam Shahrome	8	-	8	-
NLN rents a factory building from Raja Mariam Binti Raja Rustam Shahrome	8	-	8	-
OLSB rents an office space from Raja Mariam Binti Raja Rustam Shahrome	45	-	45	-

B. ADDITIONAL INFORMATION REQUIRED BY THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

B1. Review of performance

The Group recorded revenue of approximately RM40.10 million for the current quarter, an increase of approximately RM10.69 million compared to the revenue of approximately RM29.41 million in the preceding year's corresponding quarter. This was due to the revenue of approximately RM7.42 million being contributed by the newly acquired subsidiaries namely, OLSB, NLN and NLF upon completion of the acquisitions on 1 July 2020, as well as the increase in revenue of approximately RM3.27 million from the Group's existing operations. Revenue from animal health products and equipment increased by approximately RM10.23 million from approximately RM21.96 million in the preceding year's corresponding quarter to approximately RM32.19 million in the current quarter. Revenue from food ingredients also recorded an increase of approximately RM0.32 million from approximately RM6.80 million in the preceding year's corresponding quarter to approximately RM7.12 million in the current quarter.

Despite the increase in revenue contributing to an increase in gross profit of approximately RM1.41 million, the Group's profit before tax for the current quarter of approximately RM2.94 million was only approximately RM0.30 million higher compared to the profit before tax of approximately RM2.64 million reported for the preceding year's corresponding quarter. This was mainly due to the increase in administration expenses of approximately RM1.00 million as well as the increase in distribution costs of approximately RM0.10 million compared to the preceding year's corresponding quarter. The increase in administration expenses was mainly due to the inclusion of administration expenses of the newly acquired subsidiaries amounting to approximately RM0.45 million.

For the financial year-to-date under review, the Group recorded revenue of approximately RM104.68 million, an increase of approximately RM16.51 million compared to the revenue of approximately RM88.17 million in the corresponding period of the preceding year. The increase was due to the revenue of approximately RM7.42 million being contributed by the newly acquired subsidiaries namely, OLSB, NLN and NLF upon the completion of the acquisitions on 1 July 2020, as well as the increase in revenue of approximately RM9.09 million from the Group's existing operations. Revenue from animal health products and equipment increased by approximately RM13.79 million whereas food ingredients contributed to an increase in revenue of approximately RM2.61 million during the current period.

Although the increase in revenue contributed to an increase in gross profit of approximately RM3.53 million, the Group's profit before tax for the financial year-to-date under review of approximately RM7.05 million was approximately RM1.04 million lower compared to the profit before tax of approximately RM8.09 million reported for the preceding year's corresponding period. This was mainly due to the increase in administration expenses of approximately RM4.09 million as well as the increase in finance costs of approximately RM0.41 million compared to the preceding year's corresponding period. The increase in administration expenses was mainly due to higher foreign currency exchange loss of approximately RM0.68 million, higher write down of inventories of approximately RM1.27 million, professional fees of approximately RM0.54 million incurred for the acquisitions of OLSB, NLN and NLF as well as the private placement exercise during the financial year-to-date under review. The increase in administration expenses was also due to the inclusion of administration expenses of the newly acquired subsidiaries amounting to approximately RM0.45 million. In addition, there was a reversal of over provision in prior year's staff costs of approximately RM0.29 million during the preceding year's corresponding period.

B2. Material changes in the quarterly results compared to the immediate preceding quarter

The Group's revenue of approximately RM40.10 million for the current quarter was approximately RM9.41 million higher compared to the revenue of approximately RM30.69 million reported for the preceding quarter. This was due to the revenue of approximately RM7.42 million being contributed by the newly acquired subsidiaries of OLSB, NLN and NLF which the Group started consolidating subsequent to the completion of the acquisitions on 1 July 2020, as well as the increase in revenue of approximately RM1.99 million from the Group's existing operations. Revenue from animal health products increased by approximately RM8.42 million from approximately RM23.77 million in the preceding quarter to approximately RM32.19 million in the current quarter. Revenue from food ingredients also increased by approximately RM0.67 million from approximately RM6.45 million in the preceding quarter to approximately RM7.12 million in the current quarter.

The Group's profit before tax for the current quarter of approximately RM2.94 million was approximately RM2.07 million higher compared to the profit before tax of approximately RM0.87 million reported for the preceding quarter. This was mainly due to the write down of inventories of approximately RM1.57 million in the preceding quarter.

B3. Prospects

The continued expansion of our capacity and operations through our future plans would provide a platform to grow and sustain our business. The Group will continue to focus on strengthening its production capabilities, product competitiveness and market position, while constantly seeking ways to mitigate the risks associated with its business. The Group will also continue to improve its internal controls and processes based on prudent management practices.

In addition to improving on current operations, the Group is vigilant in identifying new business opportunities that has the potential for continuous growth and expansion. Accordingly, the Group has undertaken the acquisitions of OLSB, NLN and NLF in view of the favourable outlook of the livestock industry and dairy industry in Malaysia. The acquisitions are in line with the Group's strategy to tap into other segment of the animal health products i.e. ruminant segment and to venture into other related businesses with growth prospects in order to deliver positive and sustainable growth to its shareholders. With the completion of the acquisitions, the Group would now be able to broaden its product offerings, gain immediate increase in the market share of the ruminant segment and create new revenue stream in the future. This is expected to contribute positively to the Group's future earnings and enhance its financial performance in the medium to long term.

The Covid-19 pandemic that has been sweeping the globe in recent times has been anticipated to have a negative impact on the Malaysian macro-economy as well as on the economic welfare of its population. The main sources of the economic damage in Malaysia are two-fold; the first is the knock-on effect from the impacts of the Covid-19 virus abroad and the second is generated domestically due to the movement control measures imposed by the government. Notwithstanding these developments, the Group which is actively involved in the animal health and nutrition market, is within the ambit of the food industry's supply chain and is cautiously optimistic of the minimal impact that the pandemic will have on our operations.

B4. Profit forecast

The Group has not issued any profit forecast in any form of public documentation and announcement.

B5. Tax expense

	Individu	al quarter	Cumulati	ve quarter
	Current year quarter 30/09/2020 RM'000	Preceding year quarter 30/09/2019 RM'000	Current year-to-date 30/09/2020 RM'000	Preceding year-to-date 30/09/2019 RM'000
Current tax				
Current year	661	619	1,950	1,693

The effective tax rate of the Group for the current quarter of 22.49% was lower than the statutory tax rate of 24.00% due mainly to one of the Company's subsidiaries, Asia-Pacific Special Nutrients Sdn Bhd, being awarded the BioNexus status incentive and has been granted 100% income tax exemption on the statutory income for a period of ten (10) years from the first year the company derives taxable statutory income under the Income Tax (Exemption) (No.17) Order 2007 effective 23 July 2007. The first year whereby the abovementioned subsidiary commences to derive taxable statutory income was in the year 2011, thus the ten (10) years period commenced from the year 2011 until the year 2020.

The effective tax rates of the Group for the financial year-to-date of 27.68% was higher than the statutory tax rate of 24.00% as certain subsidiaries were in loss making positions and that certain expenses are non-allowable for tax purposes.

B6. Notes to the Condensed Consolidated Statement of Comprehensive Income

	Individua	al quarter	Cumulative quarter	
	Current year quarter 30/09/2020 RM'000	Preceding year quarter 30/09/2019 RM'000	Current year-to-date 30/09/2020 RM'000	Preceding year-to-date 30/09/2019 RM'000
Profit before tax is arrived at after charging / (crediting):				
Depreciation	517	364	1,176	887
Inventories written off	1,494	132	1,582	309
Inventories written (back)/down	(1,178)	180	552	540
Impairment/(write back) loss on receivables	120	(25)	240	155
(Write back)/impairment loss on other investment	(15)	12	8	12
Interest expense	297	232	1,085	673
Loss/(gain) on foreign currency exchange	141	(44)	619	(65)
Interest income	(33)	(34)	(144)	(183)

Save for the above, the other items as required under Appendix 9B Part A (16) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad are not applicable.

B7. Status of corporate proposals

There is no corporate proposal announced but not completed as at the date of this report.

B8. Other investment

	As at 30/09/2020 RM'000	As at 31/12/2019 RM'000
Financial asset at fair value through profit or loss		
Quoted shares in Malaysia	50	50
Less: Impairment loss	(18)	(10)
	32	40

B9. Borrowings

The Group's borrowings are as follows:

	As at 30/09/2020 RM'000	As at 31/12/2019 RM'000
Non-current liabilities (secured) Term loans	32,382	25,221
Current liabilities (secured) Term loans	2,323	2,066
Total borrowings	34,705	27,287

All borrowings are denominated in Ringgit Malaysia.

B10. Material litigation

There was no litigation which has a material effect on the financial position of the Group and the Board was not aware of any proceedings pending or of any fact likely to give rise to any proceedings as at the date of this report.

B11. Dividend

No dividend in respect of the financial year ending 31 December 2020 was declared or recommended for payment by the Company during the current quarter and financial year-to-date under review.

B12. Derivative financial instruments

The Group does not have any derivative financial instruments as at the end of the current quarter.

B13. Gains/losses arising from fair value changes of financial liabilities

There were no material gains or losses arising from fair value changes of financial liabilities during the current quarter and financial year-to-date under review.

B14. Earnings per share

(a) Basic earnings per share

Basic earnings per share is computed based on the profit attributable to owners of the parent divided by the weighted average number of ordinary shares in issue for the period under review.

	Individua	al quarter	Cumulativ	e quarter
	Current year quarter 30/09/2020	Preceding year quarter 30/09/2019	Current year-to-date 30/09/2020	Preceding year-to-date 30/09/2019
Profit attributable to owners of the parent (RM'000)	1,834	2,018	4,651	6,396
Weighted average number of ordinary shares in issue ('000)	200,860	182,600	193,149	182,174
Basic earnings per share (sen)	0.91	1.11	2.41	3.51

(b) Diluted earnings per share

The diluted earnings per share is equal to the basic earnings per share as there were no outstanding dilutive potential ordinary shares at the end of each reporting period.

B15. Net assets per share

Net assets per share attributable to owners of the parent is arrived at by dividing the total equity attributable to owners of the parent at the end of the financial period by the number of ordinary shares in issue at the end of the financial period.

	As at 30/09/2020	As at 31/12/2019
Total equity attributable to owners of the parent (RM'000)	121,480	107,334
Number of ordinary shares in issue ('000)	200,860	182,600
Net assets per share attributable to owners of the parent (RM)	0.60	0.59

B16. Reorganisation debit balance

The reorganisation debit balance arose from the acquisition of RMM on 28 September 2016 based on the difference between the share capital issued by the Company and the share capital issued by RMM amounting to approximately RM59.49 million.